Northwest Biotherapeutics, Inc. (NWBO) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in Bethesda, MD, United States. Der aktuelle CEO ist Linda F. Powers.
NWBO hat IPO-Datum 2001-12-14, 25 Vollzeitbeschäftigte, gelistet an der Other OTC, eine Marktkapitalisierung von $308.14M.
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.
